CHURCHILL CAPITAL CORP-CL A
CCXINASDAQTrading Snapshot
- Day Range
- $16.21 – $16.74
- 52-Week Range
- $10.07 – $19.69
- Volume
- $3.35B
- Avg Volume
- $4.22B
- Shares Outstanding
- 41.9M
- Next Earnings
- Oct 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $222M
- Last Q Revenue
- $61M
- P/E Ratio
- 1745.2
- P/S Ratio
- 0.0x
- EPS (TTM)
- $0.01
- Dividend Yield
- 0.00%
Why Investors Own CCXI
- ✓High-growth profile — revenue up +2.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 43% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About CHURCHILL CAPITAL CORP-CL A
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new drugs for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company is headquartered in Mountain View, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Churchill Capital Stock Rises as Sponsor Financing Adds Fuel to Agility Robotics Merger Plans
Churchill Capital Corp XI rise nearly 5% after securing new working capital as it advances its Agility Robotics merger.
FTC Grants Antitrust Clearance For Business Combination Between Churchill Capital And Agility Robotics
https://www.ftc.gov/legal-library/browse/early-termination-notices/20261810
Churchill Capital Corp XI Merger Partner Agility Robotics Appoints Michael Beer CFO, Succeeding Jennifer Hunter, Who Will Transition To COO Exclusively
Agility Robotics, a leading humanoid robotics and Physical AI company, today announced the appointment of Michael Beer as Chief Financial Officer as the company continues to strengthen its executive leadership team